Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Peptide-siRNA Conjugates

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Peptide

            Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

            Deal Size: $2,200.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 27, 2021

            Details:

            PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.